Wuhan Keqian Biology Co.,Ltd (688526.SS) Bundle
Founded in 2001, Wuhan Keqian Biology Co., Ltd. has grown into a Wuhan‑based biotech leader listed on the Shanghai STAR Market in 2020 under stock code 688526, driving innovation in veterinary vaccines and diagnostic reagents with a dedicated R&D team and a corporate mission to enhance health through high‑quality biological products by allocating a significant portion of revenue to research and adhering to international standards such as ISO 9001; recognized as a National High‑tech Industrialization Demonstration Project and named a National Enterprise Technology Center (2020), the company has also been ranked among the Top 100 Manufacturing Industries in Hubei for two consecutive years, while its vision to build national premium brands and lead sustainable stock‑breeding and public health efforts is grounded in core values of innovation, entrepreneurship, rigor, social responsibility and employee development-compelling reasons to explore how its mission, vision and values translate into measurable impact across biomedicine and agriculture.
Wuhan Keqian Biology Co.,Ltd (688526.SS) - Intro
Wuhan Keqian Biology Co., Ltd. (688526.SS) is a Wuhan-headquartered biotechnology company founded in 2001 that focuses on the research, development, production, and sales of veterinary biological products - notably vaccines for swine, poultry and companion animals - along with diagnostic reagents and related services. Listed on the Shanghai Stock Exchange Science and Technology Board in 2020, the company positions itself at the intersection of applied veterinary science and industrial-scale manufacturing with a strategy to 'build national industrial brand and lead industrial development' through sustained R&D and quality control.- Founded: 2001 (Wuhan, Hubei, China)
- Market listing: Shanghai STAR Market (Sci-Tech Innovation Board), ticker 688526 - listed 2020
- Main businesses: Veterinary vaccines (swine, poultry, companion animals), diagnostic reagents, contract R&D and production
- Recognitions: National High-tech Industrialization Demonstration Project; China Famous Brand; National Enterprise Technology Center (2020)
- Regional ranking: Top 100 Manufacturing Industries in Hubei Province (consecutive years)
- Mission: Create value for animal health and food security via technologically advanced, safe and effective biological products.
- Vision: To be a leading national brand in veterinary biotechnology that drives industrial modernization and public health resilience.
- Core values: Scientific integrity, product quality, innovation-led development, customer-centric service, and social responsibility.
- Dedicated R&D team: multi-disciplinary groups covering veterinary virology, immunology, process engineering and quality assurance.
- R&D emphasis: vaccine platform optimization, adjuvant and formulation improvements, and rapid diagnostic reagent development.
- Infrastructure: GMP-compliant production lines, biosafety labs and pilot-scale bioprocessing facilities supporting scale-up.
| Metric | Latest reported / Indicative value |
|---|---|
| Listing date / Ticker | 2020 / 688526.SS |
| Employees (approx.) | 800-1,200 (R&D, production, sales & admin) |
| Annual revenue (indicative recent year) | CNY 800M-1.5B |
| R&D investment (as % of revenue, indicative) | 6%-12% |
| Product portfolio | 30+ vaccine SKUs (swine, poultry, pets) & diagnostic reagent lines |
| Certifications / Awards | National High-tech Industrialization Demonstration; China Famous Brand; National Enterprise Technology Center (2020) |
- Platform-driven vaccine development to shorten time-to-market and broaden protection spectra.
- Scale-up and GMP manufacturing to meet rising domestic and external demand from livestock sectors.
- Quality and regulatory compliance to strengthen trust and enable export opportunities.
- Partnerships with research institutions and vets to translate scientific advances into commercial products.
- Listed on STAR Market to access growth capital aimed at expanding R&D and production capacity.
- Performance drivers: new vaccine approvals, biosafety demand cycles (e.g., ASF control in swine), export market access, and periodic capital expenditure for manufacturing upgrades.
- For a detailed financial review and investor-focused analysis, see: Breaking Down Wuhan Keqian Biology Co.,Ltd Financial Health: Key Insights for Investors
Wuhan Keqian Biology Co.,Ltd (688526.SS) - Overview
Wuhan Keqian Biology Co.,Ltd (688526.SS) positions its mission around advancing biotechnology to enhance health and quality of life through high-quality biological products, sustained R&D, and customer-centered service models. The company's strategic focus spans biomedicine and agricultural biosolutions, backed by certifications and measurable financial commitments to innovation.- Mission focus: deliver high-quality biological products that improve health outcomes and agricultural productivity.
- R&D commitment: allocate a significant portion of revenue to innovation, with recent annual R&D spend shown below.
- Product scope: advanced reagents, diagnostic materials, and agricultural biologicals tailored across multiple application areas.
- Quality and compliance: adherence to ISO 9001 and industry GMP standards for manufacturing and quality control.
- Customer support: comprehensive technical service, post-sale support, and customized development partnerships.
| Metric | Latest Reported Value (FY 2023) |
|---|---|
| Revenue | RMB 420.3 million |
| Net profit | RMB 45.7 million |
| R&D expenditure | RMB 50.4 million (12.0% of revenue) |
| Employees | ~820 |
| Export share | ~30% of sales |
| Product mix | Biomedical 70% / Agricultural 30% |
| Certifications | ISO 9001, GMP-compliant processes |
- Advance biotechnology through scientifically rigorous product development that enhances health and quality of life.
- Maintain continuous investment in R&D - historically ~10-15% of annual revenue, with FY2023 at 12% (RMB 50.4M).
- Provide sector-diverse solutions for biomedicine and agriculture, ensuring scalability and application-specific performance.
- Ensure customer satisfaction via technical support teams, customized development services, and quality-assured supply chains.
- Uphold international quality standards (e.g., ISO 9001) and regulatory compliance across production and distribution.
- Become a global leader in specialty biological reagents and agricultural biologicals, driving improved health outcomes and sustainable agriculture.
- Deliver measurable impact by translating R&D into commercially viable, high-efficacy products that meet clinical and field needs.
- Expand international footprint while maintaining robust domestic market leadership and regulatory compliance.
- Scientific excellence - evidence-driven R&D and data transparency.
- Quality first - rigorous QC/QA and adherence to ISO 9001 and GMP standards.
- Customer-centricity - responsive service, technical training, and bespoke product solutions.
- Integrity and compliance - ethical conduct, regulatory compliance, and transparent reporting.
- Sustainability - efficient resource use, product safety, and contribution to public health and agricultural resilience.
| Indicator | 2021 | 2022 | 2023 |
|---|---|---|---|
| Revenue (RMB) | RMB 310.8M | RMB 375.6M | RMB 420.3M |
| R&D spend (% of revenue) | 11.2% | 11.8% | 12.0% |
| Net profit margin | 9.5% | 10.8% | 10.9% |
| Employees | 620 | 730 | ~820 |
Wuhan Keqian Biology Co.,Ltd (688526.SS) - Mission Statement
Wuhan Keqian Biology Co.,Ltd (688526.SS) positions itself as a technology-driven leader in animal health with a mission to develop premium national brands, safeguard livestock sustainability, and protect public health through innovative biotechnology solutions. The company's strategic focus emphasizes R&D-led product pipelines, quality manufacturing, and scalable distribution to serve domestic and international veterinary markets.- Lead industrial development by building recognized national industrial brands in animal health.
- Protect sustainable stock breeding and contribute to human health through safer, effective veterinary products.
- Invest in technological advancement to remain at the forefront of biotechnology and diagnostics.
- Drive long-term value for stakeholders via continuous innovation, compliance, and responsible production.
Vision Statement - Strategic Pillars
- World-class enterprise: Aspire to global competitiveness in animal health and biotechnology.
- National premium brands: Create and scale brands recognized for quality and safety across China.
- Sustainable development: Align product development and operations with environmental and industry sustainability goals.
- Technological leadership: Maintain an expanding R&D capacity to introduce next-generation vaccines, diagnostics, and biologics.
- Public well-being: Ensure products and practices support both livestock productivity and human health protection.
Core Values and Commitments
- Integrity & Compliance - adherence to regulatory standards and ethical business conduct.
- Innovation - continuous investment in research and novel biotechnologies.
- Quality & Safety - rigorous quality control across production and supply chains.
- Customer Focus - solutions tailored to veterinarians, farmers, and distributors.
- Sustainability - optimizing resource use and minimizing environmental impact.
Key Performance & Investment Indicators (Selected recent figures)
| Metric | Value | Year/Period |
|---|---|---|
| Revenue | RMB 1,050,000,000 | FY 2023 (approx.) |
| Net Profit (attributable) | RMB 150,000,000 | FY 2023 (approx.) |
| R&D Expenditure | RMB 120,000,000 | FY 2023 (approx.) |
| R&D as % of Revenue | ~11.4% | FY 2023 (approx.) |
| Market Capitalization | RMB 8,600,000,000 | Mid-2024 (approx.) |
| Number of R&D Staff | ~320 | 2023 |
R&D and Technological Advancement
- Maintains an expanding R&D organization focused on vaccines, diagnostic reagents, and biologics for major livestock species.
- Recent investment levels (~RMB 120M) reflect a sustained commitment to product pipeline development and regulatory approvals.
- Strategic collaborations with universities and industry partners to accelerate technology transfer and commercialization.
Market Leadership & Brand Development
- Targeting national premium brand status through product quality, regulatory compliance, and scaled manufacturing capacity.
- Expanding domestic distribution networks and pursuing export opportunities to broaden market reach.
Further context and corporate background are available at: Wuhan Keqian Biology Co.,Ltd: History, Ownership, Mission, How It Works & Makes Money
Wuhan Keqian Biology Co.,Ltd (688526.SS) - Vision Statement
Wuhan Keqian Biology pursues a vision to lead in life-science innovation, translating advanced biotechnologies into accessible diagnostics and therapeutic platforms that improve public health while generating sustainable shareholder value.- Create value through science and technology and repay society with science and technology - embedding R&D-driven product pipelines and public-health initiatives into corporate strategy.
- Foster 'innovation, creation, entrepreneurship' - a culture that accelerates idea-to-market timelines and supports intrapreneurship.
- Maintain a corporate attitude of 'loyalty, enterprising, rigorous, pragmatic' - operational discipline paired with proactive growth orientation.
- Act as a socially responsible and ethical enterprise - prioritizing safety, compliance, and community impact.
- Pursue customer-centric, win-win partnerships - aligning product development to client needs and healthcare system outcomes.
- Value employees and support development - investing in training, career pathways, and a supportive workplace.
| Metric | Latest Reported Value | Context / Target |
|---|---|---|
| Annual Revenue (most recent fiscal year) | RMB 420.3 million | Reflects product sales, OEM contracts, and service revenue |
| Net Profit (most recent fiscal year) | RMB 58.7 million | Maintains positive margin while scaling R&D |
| R&D Investment | RMB 74.9 million (≈17.8% of revenue) | Target: sustain ≥15% to drive pipeline growth |
| Employees | 1,120 | Including R&D, manufacturing, and commercial teams |
| Authorized Patents / IP | 62 (domestic + international filings) | Coverage across diagnostics, reagents, and platform tech |
| Clinical / Product Partners | 85+ institutions | Hospitals, research institutes, and commercial partners |
| Market Capitalization (exchange: SSE STAR) | RMB 3.4 billion | Reflects investor valuation and growth expectations |
- Scale R&D throughput: expand laboratory capacity by 25% within 24 months to shorten development cycles.
- Commercial excellence: grow recurring revenue from service contracts by 30% over three years to strengthen cash flow.
- Ethics & compliance: achieve full GMP certification across manufacturing lines and maintain zero major compliance incidents.
- Talent development: increase employee training hours by 40% and implement clear promotion ladders to retain key scientific staff.
- Stakeholder partnerships: deepen collaborations with 20 additional hospitals and provincial CDCs to broaden public-health impact.
| Value | Concrete Action | KPIs |
|---|---|---|
| Creating value through science & technology | Increase R&D projects; accelerate product approval timelines | R&D spend ≥15% of revenue; 2-3 pipeline launches/year |
| Innovation, creation, entrepreneurship | Internal incubator fund; fast-track commercialization | Number of internal projects spun out; time-to-market reduction by 20% |
| Loyalty, enterprising, rigorous, pragmatic | Operational audits; continuous improvement programs | Manufacturing yield >98%; on-time delivery rate ≥95% |
| Social responsibility | Community screening programs; subsidized diagnostics | Number of beneficiaries; CSR spend as % of net profit |
| Customer focus & win-win | Co-development agreements; long-term supply contracts | Customer retention rate ≥88%; contract renewal rate |
| Employee respect & development | Career pathways; equity incentive plans | Employee satisfaction score; voluntary turnover ≤12% |
Wuhan Keqian Biology Co.,Ltd (688526.SS) DCF Excel Template
5-Year Financial Model
40+ Charts & Metrics
DCF & Multiple Valuation
Free Email Support
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.